Biomaterial Database

Mitoxantrone therapy in rapidly worsening multiple sclerosis. 2005

Y Benesova, and P Stourac, and M Beranek, and Z Kadanka

Department of Neurology, University Hospital, Brno, Czech Republic. benes@fnbrno.cz

BACKGROUND This study evaluates mitoxantrone (MX) therapy in patients with relapsing remitting and secondary progressive multiple sclerosis (MS). OBJECTIVE Evaluation of the disability progression and side effects of MX. METHODS There were studied 33 patients (10 males, 23 females), average age 48.5+/-9.9 SD) with relapsing remitting and secondary progressive MS. The disability was evaluated using Expanded Disability Status Scale (EDSS). Time period from the onset to secondary progressive course of the disease was 9.3 years. Patients, whose disability progression increased by one or more EDSS point per one year, and not responding to other therapy, were treated with mitoxantrone. Patients were treated once monthly with intravenous administration of mitoxantrone 12 mg/m2, not exceeding the maximum cumulative dose of 14 mg/m2 and Solu-Medrol 1000 mg. Six pulses were done in each patient. EDSS score was measured at the beginning of the treatment and after twelwe month. Disability progression was evaluated. Nonparametric Wilcoxon matched pair test was used for statistical analysis. (Tab. 1, Fig. 3, Ref: 5.)

UI	MeSH Term	Description	Entries
D008297	Male		Males
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D008942	Mitoxantrone	An anthracenedione-derived antineoplastic agent.	Mitozantrone,CL-232325,DHAQ,Mitoxantrone Acetate,Mitoxantrone Hydrochloride,Mitroxone,NSC-279836,NSC-287836,NSC-299195,NSC-301739,NSC-301739D,Novantron,Novantrone,Onkotrone,Pralifan,Ralenova,Acetate, Mitoxantrone,CL 232325,CL232325,Hydrochloride, Mitoxantrone,NSC 279836,NSC 287836,NSC 299195,NSC 301739,NSC 301739D,NSC279836,NSC287836,NSC299195,NSC301739,NSC301739D
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D018450	Disease Progression	The worsening and general progression of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.	Clinical Course,Clinical Progression,Disease Exacerbation,Exacerbation, Disease,Progression, Clinical,Progression, Disease
D020528	Multiple Sclerosis, Chronic Progressive	A form of multiple sclerosis characterized by a progressive deterioration in neurologic function which is in contrast to the more typical relapsing remitting form. If the clinical course is free of distinct remissions, it is referred to as primary progressive multiple sclerosis. When the progressive decline is punctuated by acute exacerbations, it is referred to as progressive relapsing multiple sclerosis. The term secondary progressive multiple sclerosis is used when relapsing remitting multiple sclerosis evolves into the chronic progressive form. (From Ann Neurol 1994;36 Suppl:S73-S79; Adams et al., Principles of Neurology, 6th ed, pp903-914)	Chronic Progressive Multiple Sclerosis,Multiple Sclerosis, Progressive Relapsing,Multiple Sclerosis, Remittent Progressive,Multiple Sclerosis, Primary Progressive,Multiple Sclerosis, Secondary Progressive,Primary Progressive Multiple Sclerosis,Progressive Relapsing Multiple Sclerosis,Remittent Progressive Multiple Sclerosis,Secondary Progressive Multiple Sclerosis
D020529	Multiple Sclerosis, Relapsing-Remitting	The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)	Multiple Sclerosis, Acute Relapsing,Relapsing-Remitting Multiple Sclerosis,Acute Relapsing Multiple Sclerosis,Remitting-Relapsing Multiple Sclerosis,Multiple Sclerosis, Relapsing Remitting,Multiple Sclerosis, Remitting-Relapsing,Relapsing Remitting Multiple Sclerosis,Remitting Relapsing Multiple Sclerosis